Tags

Type your tag names separated by a space and hit enter

Relationship between histamine2-receptor antagonist medications and risk of invasive breast cancer.
Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):67-72.CE

Abstract

BACKGROUND

Histamine(2)-receptor antagonist (H(2) blocker) medications are used to treat heartburn, gastroesophageal reflux disease, and ulcers. Some H(2) blockers, specifically cimetidine and ranitidine, also increase serum prolactin concentrations. Given the positive relationship between prolactin levels and postmenopausal breast cancer risk, use of H(2) blockers is a potential breast cancer risk factor. The few previous studies evaluating this association have been null but have been limited by small sample sizes, and none have evaluated risk by either histologic type or estrogen receptor/progesterone receptor status.

METHODS

Combining data from two population-based case-control studies conducted in western Washington, we assessed the relationship between use of H(2) blockers and risk of different types of breast cancer among 1,941 cases and 1,476 controls 55 to 79 years old. Odds ratios and 95% confidence intervals (95% CI) were calculated using polytomous logistic regression.

RESULTS

Current use of H(2) blockers overall, cimetidine, and famotidine was not associated with an increased risk of either invasive ductal or invasive lobular breast cancer. Current users of ranitidine had a 2.2-fold (95% CI, 1.1-4.3) increased risk of ductal carcinoma that was confined to a 2.4-fold (95% CI, 1.2-4.9) increased risk of estrogen receptor-positive/progesterone receptor-positive ductal carcinoma.

CONCLUSIONS

Use of H(2) blockers in general is not associated with an increased risk of breast cancer, although current use of ranitidine may increase risk of hormone receptor-positive ductal carcinoma. Further studies to confirm this finding are warranted.

Authors+Show Affiliations

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA. rmathes@u.washington.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

18199712

Citation

Mathes, Robert W., et al. "Relationship Between Histamine2-receptor Antagonist Medications and Risk of Invasive Breast Cancer." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 17, no. 1, 2008, pp. 67-72.
Mathes RW, Malone KE, Daling JR, et al. Relationship between histamine2-receptor antagonist medications and risk of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(1):67-72.
Mathes, R. W., Malone, K. E., Daling, J. R., Porter, P. L., & Li, C. I. (2008). Relationship between histamine2-receptor antagonist medications and risk of invasive breast cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 17(1), 67-72. https://doi.org/10.1158/1055-9965.EPI-07-0765
Mathes RW, et al. Relationship Between Histamine2-receptor Antagonist Medications and Risk of Invasive Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(1):67-72. PubMed PMID: 18199712.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Relationship between histamine2-receptor antagonist medications and risk of invasive breast cancer. AU - Mathes,Robert W, AU - Malone,Kathleen E, AU - Daling,Janet R, AU - Porter,Peggy L, AU - Li,Christopher I, PY - 2008/1/18/pubmed PY - 2008/4/2/medline PY - 2008/1/18/entrez SP - 67 EP - 72 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 17 IS - 1 N2 - BACKGROUND: Histamine(2)-receptor antagonist (H(2) blocker) medications are used to treat heartburn, gastroesophageal reflux disease, and ulcers. Some H(2) blockers, specifically cimetidine and ranitidine, also increase serum prolactin concentrations. Given the positive relationship between prolactin levels and postmenopausal breast cancer risk, use of H(2) blockers is a potential breast cancer risk factor. The few previous studies evaluating this association have been null but have been limited by small sample sizes, and none have evaluated risk by either histologic type or estrogen receptor/progesterone receptor status. METHODS: Combining data from two population-based case-control studies conducted in western Washington, we assessed the relationship between use of H(2) blockers and risk of different types of breast cancer among 1,941 cases and 1,476 controls 55 to 79 years old. Odds ratios and 95% confidence intervals (95% CI) were calculated using polytomous logistic regression. RESULTS: Current use of H(2) blockers overall, cimetidine, and famotidine was not associated with an increased risk of either invasive ductal or invasive lobular breast cancer. Current users of ranitidine had a 2.2-fold (95% CI, 1.1-4.3) increased risk of ductal carcinoma that was confined to a 2.4-fold (95% CI, 1.2-4.9) increased risk of estrogen receptor-positive/progesterone receptor-positive ductal carcinoma. CONCLUSIONS: Use of H(2) blockers in general is not associated with an increased risk of breast cancer, although current use of ranitidine may increase risk of hormone receptor-positive ductal carcinoma. Further studies to confirm this finding are warranted. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/18199712/Relationship_between_histamine2_receptor_antagonist_medications_and_risk_of_invasive_breast_cancer_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=18199712 DB - PRIME DP - Unbound Medicine ER -